Advertisement


Qi Liu, PhD, on NSCLC: Pneumonitis, Immunotherapy, and Chemotherapy

AACR Virtual Annual Meeting 2020

Advertisement

Qi Liu, PhD, of the U.S. Food and Drug Administration, discusses data that suggest that patients with advanced non–small cell lung cancer who had a past medical history of pneumonitis were more likely to experience treatment-associated pneumonitis in response to immune checkpoint inhibitors or chemotherapy (Abstract CT086).



Related Videos

Skin Cancer
Immunotherapy

Grant A. McArthur, MBBS, PhD, on Melanoma: IMspire150 Trial of Atezolizumab, Cobimetinib, and Vemurafenib

Grant A. McArthur, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses phase III results from a study of previously untreated patients with BRAF V600 mutation...

Breast Cancer

Jennifer K. Litton, MD, on Breast Cancer: EMBRACA Trial on Talazoparib vs Chemotherapy

Jennifer K. Litton, MD, of The University of Texas MD Anderson Cancer Center, discusses study results of talazoparib vs chemotherapy in patients with BRCA1/2-mutated...

Lung Cancer

Edward B. Garon, MD, on Metastatic NSCLC: GEOMETRY mono-1 Trial of Capmatinib

Edward B. Garon, MD, of the University of California, Los Angeles, David Geffen School of Medicine, discusses results from a small study in METex14-mutated advanced ...

Lung Cancer
Immunotherapy

Byoung Chul Cho, MD, PhD, on NSCLC: Genetic Mutations and Immunotherapy vs Chemotherapy in KEYNOTE-042

Byoung Chul Cho, MD, PhD, of Yonsei Cancer Center and Severance Hospital, discusses the STK11 and KEAP1 mutations in non–small cell lung cancers, and their ...

Breast Cancer
Immunotherapy

Lajos Pusztai, MD, PhD, on Breast Cancer: I-SPY2 Trial on Durvalumab, Olaparib, and Paclitaxel

Lajos Pusztai, MD, PhD, of Yale Cancer Center, discusses study results on durvalumab in combination with olaparib and paclitaxel as neoadjuvant treatment in patients with hig...

Advertisement

Advertisement



Advertisement